Deka Bank Deutsche Girozentrale Apellis Pharmaceuticals, Inc. Transaction History

Deka Bank Deutsche Girozentrale

$53.9 Billion
Q3 2024

A detailed history of Deka Bank Deutsche Girozentrale transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Deka Bank Deutsche Girozentrale holds 55,000 shares of APLS stock, worth $1.79 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

55,000

Previous 55,000 -0.0%

Holding current value

$1.79 Million

Previous $2.25 Million 30.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$23.65 - $89.22 $1.3 Million - $4.91 Million	55,000 New	55,000 $2.15 Million
Q3 2022 Nov 02, 2022	SELL	$44.76 - $69.66 $344,652 - $536,382	-7,700 Reduced 13.34%	50,000 $3.18 Million
Q2 2022 Aug 03, 2022	BUY	$35.07 - $59.21 $1.09 Million - $1.84 Million	31,000 Added 116.1%	57,700 $2.55 Million
Q1 2022 Apr 28, 2022	SELL	$35.46 - $54.12 $592,182 - $903,804	-16,700 Reduced 38.48%	26,700 $1.32 Million
Q4 2021 Feb 02, 2022	BUY	$30.74 - $49.16 $574,838 - $919,291	18,700 Added 75.71%	43,400 $2.04 Million
Q3 2021 Oct 22, 2021	SELL	$31.4 - $69.84 $439,600 - $977,760	-14,000 Reduced 36.18%	24,700 $824,000
Q2 2021 Aug 05, 2021	SELL	$40.9 - $64.9 $490,800 - $778,800	-12,000 Reduced 23.67%	38,700 $2.43 Million
Q4 2020 Mar 12, 2021	SELL	$30.79 - $57.2 $354,085 - $657,800	-11,500 Reduced 18.49%	50,700 $2.77 Million
Q3 2020 Oct 29, 2020	BUY	$25.89 - $33.65 $1.61 Million - $2.09 Million	62,200 New	62,200 $1.78 Million
Q3 2019 Nov 14, 2019	SELL	$24.09 - $32.18 $3.23 Million - $4.31 Million	-134,000 Closed	0 $0
Q2 2019 Aug 01, 2019	BUY	$18.0 - $25.34 $2.41 Million - $3.4 Million	134,000 New	134,000 $3.28 Million

Others Institutions Holding APLS

# of Institutions

309

Shares Held

115M

Call Options Held

3.85M

Put Options Held

1.09M

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.58B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deka Bank Deutsche Girozentrale, based on Form 13F filings with the SEC.

News

Stay updated on Deka Bank Deutsche Girozentrale with notifications on news.

Account

Deka Bank Deutsche Girozentrale Apellis Pharmaceuticals, Inc. Transaction History